Liposome based drug delivery as a potential treatment option for Alzheimer’s disease
Alzheimer’s disease is a neurodegenerative condition leading to atrophy of the brain and robbing nearly 5.8 million individuals in the United States age 65 and older of their cognitive functions. Alzheimer’s disease is associated with dementia and a progressive decline in memory, thinking, and socia...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Wolters Kluwer Medknow Publications
2022
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/816dac8721d541b5954245e9e47ce1ce |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:816dac8721d541b5954245e9e47ce1ce |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:816dac8721d541b5954245e9e47ce1ce2021-11-19T12:16:44ZLiposome based drug delivery as a potential treatment option for Alzheimer’s disease1673-537410.4103/1673-5374.327328https://doaj.org/article/816dac8721d541b5954245e9e47ce1ce2022-01-01T00:00:00Zhttp://www.nrronline.org/article.asp?issn=1673-5374;year=2022;volume=17;issue=6;spage=1190;epage=1198;aulast=Hernandezhttps://doaj.org/toc/1673-5374Alzheimer’s disease is a neurodegenerative condition leading to atrophy of the brain and robbing nearly 5.8 million individuals in the United States age 65 and older of their cognitive functions. Alzheimer’s disease is associated with dementia and a progressive decline in memory, thinking, and social skills, eventually leading to a point that the individual can no longer perform daily activities independently. Currently available drugs on the market temporarily alleviate the symptoms, however, they are not successful in slowing down the progression of Alzheimer’s disease. Treatment and cures have been constricted due to the difficulty of drug delivery to the blood-brain barrier. Several studies have led to identification of vesicles to transport the necessary drugs through the blood-brain barrier that would typically not achieve the targeted area through systemic delivered medications. Recently, liposomes have emerged as a viable drug delivery agent to transport drugs that are not able to cross the blood-brain barrier. Liposomes are being used as a component of nanoparticle drug delivery; due to their biocompatible nature; and possessing the capability to carry both lipophilic and hydrophilic therapeutic agents across the blood brain barrier into the brain cells. Studies indicate the importance of liposomal based drug delivery in treatment of neurodegenerative disorders. The idea is to encapsulate the drugs inside the properly engineered liposome to generate a response of treatment. Liposomes are engineered to target specific diseased moieties and also several surface modifications of liposomes are under research to create a clinical path to the management of Alzheimer’s disease. This review deals with Alzheimer’s disease and emphasize on challenges associated with drug delivery to the brain, and how liposomal drug delivery can play an important role as a drug delivery method for the treatment of Alzheimer’s disease. This review also sheds some light on variation of liposomes. Additionally, it emphasizes on the liposomal formulations which are currently researched or used for treatment of Alzheimer’s disease and also discusses the future prospect of liposomal based drug delivery in Alzheimer’s disease.Carely HernandezSurabhi ShuklaWolters Kluwer Medknow Publicationsarticlealzheimer′s disease; beta-amyloid; blood-brain barrier; brain delivery; drug delivery systems; encapsulated drugs; liposomes; nanoparticles; neurodegenerative diseases; pegylation; targeted delivery; tauNeurology. Diseases of the nervous systemRC346-429ENNeural Regeneration Research, Vol 17, Iss 6, Pp 1190-1198 (2022) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
alzheimer′s disease; beta-amyloid; blood-brain barrier; brain delivery; drug delivery systems; encapsulated drugs; liposomes; nanoparticles; neurodegenerative diseases; pegylation; targeted delivery; tau Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
alzheimer′s disease; beta-amyloid; blood-brain barrier; brain delivery; drug delivery systems; encapsulated drugs; liposomes; nanoparticles; neurodegenerative diseases; pegylation; targeted delivery; tau Neurology. Diseases of the nervous system RC346-429 Carely Hernandez Surabhi Shukla Liposome based drug delivery as a potential treatment option for Alzheimer’s disease |
| description |
Alzheimer’s disease is a neurodegenerative condition leading to atrophy of the brain and robbing nearly 5.8 million individuals in the United States age 65 and older of their cognitive functions. Alzheimer’s disease is associated with dementia and a progressive decline in memory, thinking, and social skills, eventually leading to a point that the individual can no longer perform daily activities independently. Currently available drugs on the market temporarily alleviate the symptoms, however, they are not successful in slowing down the progression of Alzheimer’s disease. Treatment and cures have been constricted due to the difficulty of drug delivery to the blood-brain barrier. Several studies have led to identification of vesicles to transport the necessary drugs through the blood-brain barrier that would typically not achieve the targeted area through systemic delivered medications. Recently, liposomes have emerged as a viable drug delivery agent to transport drugs that are not able to cross the blood-brain barrier. Liposomes are being used as a component of nanoparticle drug delivery; due to their biocompatible nature; and possessing the capability to carry both lipophilic and hydrophilic therapeutic agents across the blood brain barrier into the brain cells. Studies indicate the importance of liposomal based drug delivery in treatment of neurodegenerative disorders. The idea is to encapsulate the drugs inside the properly engineered liposome to generate a response of treatment. Liposomes are engineered to target specific diseased moieties and also several surface modifications of liposomes are under research to create a clinical path to the management of Alzheimer’s disease. This review deals with Alzheimer’s disease and emphasize on challenges associated with drug delivery to the brain, and how liposomal drug delivery can play an important role as a drug delivery method for the treatment of Alzheimer’s disease. This review also sheds some light on variation of liposomes. Additionally, it emphasizes on the liposomal formulations which are currently researched or used for treatment of Alzheimer’s disease and also discusses the future prospect of liposomal based drug delivery in Alzheimer’s disease. |
| format |
article |
| author |
Carely Hernandez Surabhi Shukla |
| author_facet |
Carely Hernandez Surabhi Shukla |
| author_sort |
Carely Hernandez |
| title |
Liposome based drug delivery as a potential treatment option for Alzheimer’s disease |
| title_short |
Liposome based drug delivery as a potential treatment option for Alzheimer’s disease |
| title_full |
Liposome based drug delivery as a potential treatment option for Alzheimer’s disease |
| title_fullStr |
Liposome based drug delivery as a potential treatment option for Alzheimer’s disease |
| title_full_unstemmed |
Liposome based drug delivery as a potential treatment option for Alzheimer’s disease |
| title_sort |
liposome based drug delivery as a potential treatment option for alzheimer’s disease |
| publisher |
Wolters Kluwer Medknow Publications |
| publishDate |
2022 |
| url |
https://doaj.org/article/816dac8721d541b5954245e9e47ce1ce |
| work_keys_str_mv |
AT carelyhernandez liposomebaseddrugdeliveryasapotentialtreatmentoptionforalzheimersdisease AT surabhishukla liposomebaseddrugdeliveryasapotentialtreatmentoptionforalzheimersdisease |
| _version_ |
1718420078454636544 |